Red: Avoid combination

Label

Interaction expected – Do not coadminister

Color

Red

Icon

Close Octagon Outline

Displaying 101 - 200 of 332

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Atazanavir RIF 837	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 57%, Cmax decreased 56%, Cmin decreased 93%(compared to atazanavir 400 mg daily)	600 mg daily x 10 d	Not reported	Contraindicated. Use alternative agents.
Atazanavir RIF 836	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 31%, Cmax decreased 40%, Cmin decreased 80%(compared to atazanavir 400 mg daily)	600 mg daily x 10 d	Not reported	Contraindicated. Use alternative agents.
Atazanavir CBZ 835	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy				Contraindicated. Use alternative agents.
Atazanavir Phenytoin 834	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Contraindicated. Use alternative agents.
Atazanavir Phenobarbital 833	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Contraindicated. Use alternative agents.
Atazanavir St. John's Wort (Hypericum perforatum) 832	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiretroviral efficacy				Contraindicated. Use alternative agents.
Atazanavir Simvastatin 831	Red: Avoid combination	Do not coadminister: Potential for increased levels of simvastatin	Potential Increased simvastatin effects (eg, myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Atazanavir Salmeterol 830	Red: Avoid combination	Do not coadminister: Potential for increased levels of salmeterol	QT prolongation, palpitations, and sinus tachycardia.				Contraindicated. Use alternative agents.
Atazanavir Ranolazine 829	Red: Avoid combination	Do not coadminister: Potential for increased levels of ranolazine	Potential increase in ranolazine adverse effects (e.g. prolonged QT, cardiac arrythmias).				Contraindicated. Use alternative agents.
Atazanavir Quetiapine 828	Red: Avoid combination	Do not coadminister: Potential for increased levels of quentiapine. If coadministration is necessary: reduce dose to 1 / 6 of current dose.	Increased quentiapine effects.				Contraindicated. Use alternative agents.
Atazanavir Pimozide 827	Red: Avoid combination	Do not coadminister: Potential for increased levels of pimozide	Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)				Contraindicated. Use alternative agents.
Atazanavir Lurasidone 826	Red: Avoid combination	Do not coadminister: Potential for increased levels of lurasidone	Potential increased in pimozide adverse effects (eg, hypotension, cardiac arrhythmias)				Contraindicated. Use alternative agents.
Atazanavir HMG-CoA Reductase Inhibitors 825	Red: Avoid combination	Do not coadminister: Potential for increased levels of lovastatin	Increased lovastatin effects (eg, myopathy, rhabdomyolysis)				Contraindicated. Use alternative agents.
Atazanavir NVP 824	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition		Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	Contraindicated. Use alternative agents.
Atazanavir EBR/GZR 823	Red: Avoid combination	Do not coadminister: Potential for increased levels of grazoprevir	May increase risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	ATV AUC increased 43% by grazoprevir	Elbasvir 50 mg daily with grazoprevir 200 mg daily	Elbasvir AUC increased by 4.76-fold, Grazoprevir AUC increased by 10.58-fold	Contraindicated. Use alternative agents.
Atazanavir Ergotamine 822	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Potential for increased ergotamine effects (eg, ergotism)				Contraindicated. Use alternative agents.
Atazanavir RTV 821	Red: Avoid combination	Do not coadminister: Potential for increased levels of atazanavir	Potential atazanavir-associated adverse effects (hyperbilirubinemia, GI upset, etc.)	Not studied; Potential increased atazanavir levels)			Do not coadminister ritonavir or ritonavir containing products with atazanavir / cobicistat
Atazanavir Triazolam 820	Red: Avoid combination	Do not coadminister: Potential for increased levels of triazolam	Potential for increased triazolam adverse effects (eg, increased sedation, confusion, respiratory depression)				Contraindicated. Use alternative agents.
Atazanavir SOF/VEL/VOX 819	Red: Avoid combination	Do not coadminister: Increased levels of voxilaprevir					Contraindicated. Use alternative agents.
Atazanavir Irinotecan 818	Red: Avoid combination	Do not coadminister: Increased levels of irinotecan					Contraindicated. Use alternative agents.
Atazanavir Alfuzosin 817	Red: Avoid combination	Do not coadminister: Increased levels of alfuzosin					Contraindicated. Use alternative agents.
Tenofovir disoproxil fumarate Adefovir 747	Red: Avoid combination	Do not coadminister: Potential for increased levels of TDF	Potential for increased risk of TDF adverse effects and / or increased concentration of other renally eliminated drugs	No significant change	10 mg once daily	No significant change	Avoid combination and use alternative agents
Tenofovir alafenamide CBZ 725	Red: Avoid combination	Do not coadminister: Reduced levels of TAF	Potential decrease in antiretroviral efficacy	Cmax decreased 57%, AUC decreased 55%	300 mg BID	Not reported	Contraindicated. Use alternative agents.
Tenofovir alafenamide St. John's Wort (Hypericum perforatum) 724	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide RPT 723	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide Primidone 722	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide Phenytoin 721	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide Phenobarbital 720	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide Oxcarbazepine 719	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide RIF 718	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Dosed once: AUC decreased 55%; dosed twice: AUC decreased 14%		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide RFB 717	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Potential decrease in antiretroviral efficacy	Not studied		Not studied	Contraindicated. Use alternative agents.
Tenofovir alafenamide Adefovir 716	Red: Avoid combination	Do not coadminister: Potential for increased levels of TAF	Potential for increased renal adverse effects	Not studied		Not studied	Contraindicated. Use alternative agents.
Rilpivirine RFB 665	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Decreased rilpivirine effects	Rilpivirine AUC decreased 46%; Cmin decreased 49%; Cmax decreased 35%	300 mg daily		Use alternative agents
Rilpivirine RIF 664	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Decreased rilpivirine effects	Rilpivirine AUC decreased 80%; Cmin decreased 89%; Cmax decreased 69%	600 mg daily	No significant change	Use alternative agents
Rilpivirine Omeprazole 663	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine	Decreased rilpivirine effects	Rilpivirine AUC decreased 40%; Cmin decreased 33%; Cmax decreased 40%	20 mg daily	No significant change	Contraindicated. Use alternative agents.
Rilpivirine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 662	Red: Avoid combination	Do not coadminister: Increased levels of rilpivirine	Potential for QT interval prolongation with higher concentrations of RPV.	RPV increased 155%; AUC increased 225%; Cmin increased 262%	paritaprevir 150 mg with ritonavir 100 mg with ombitasvir 25 mg daily + dasabuvir 250 mg BID	Dasabuvir Cmax increased 18%; AUC increased 17%; Cmin increased 10%. Ombitasvir AUC increased 9%. Paritaprevir Cmin increased 30%, AUC increased 23%; Cmin decreased 5%.	Use alternative agents
Rilpivirine RPT 661	Red: Avoid combination	Do not coadminister: Reduced levels of rilpivirine
Rilpivirine St. John's Wort (Hypericum perforatum) 660	Red: Avoid combination	Contraindicated
Rilpivirine Oxcarbazepine 659	Red: Avoid combination	Contraindicated
Rilpivirine CBZ 658	Red: Avoid combination	Contraindicated
Nevirapine SOF/VEL 629	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir and voxilaprevir	Potential loss of anti-HCV efficacy			Not studied (may decrease velpatasvir and voxilaprevirlevels)	Contraindicated. Use alternative agents.
Nevirapine SOF/VEL 628	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir	Potential loss of anti-HCV efficacy			Not studied (may decrease velpatasvir levels)	Contraindicated. Use alternative agents.
Nevirapine Cariprazine 627	Red: Avoid combination	Do not coadminister: potientially reduced levels of cariprazine	Potential decreased cariprazine effects				Contraindicated. Use alternative agents.
Nevirapine Pimavanserin 626	Red: Avoid combination	Do not coadminister: Reduced levels of pimavanserin	Decreased pimavanserin levels				Avoid combination and use alternative agents
Nevirapine RIF 625	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects		600 mg daily		Use alternative agents
Nevirapine RIF 624	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects		450 mg if < 55 kg and 600 mg if > 55 kg x 7 days		Use alternative agents
Nevirapine RIF 623	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects			Not studied	Use alternative agents
Nevirapine RIF 622	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects		600 mg daily	No significant change	Use alternative agents
Nevirapine RPT 621	Red: Avoid combination	Do not coadminister: Reduced levels of nevirapine	Decreased nevirapine effects			Cmin decreased 27%	Contraindicated. Use alternative agents.
Nevirapine Lumateperone 620	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Decreased Lumateperon levels				Avoid combination and use alternative agents
Nevirapine LNG 619	Red: Avoid combination	Do not coadminister: Reduced levels of levonorgestrel				Levonorgestrel AUC increased 35%
Nevirapine Ketoconazole 618	Red: Avoid combination	Do not coadminister: Reduced levels of ketoconazole	Decreased ketoconazole effects		400 mg daily	Ketoconazole AUC decreased 72%; Cmax decreased 44%	Use alternative agents
Nevirapine ETR 617	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Decreased etravirine and nevirapine effects	levels): increased 15-30%		Etravirine AUC decreased 55%	Use alternative agents
Nevirapine Ethinyl estradiol / Norethindrone acetate 616	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol and progesterone	Possible contraceptive failure		Ethinyl estradiol 0.035 mg / Norethindrone 1 mg daily x 30 days	Ethinyl estradiol: AUC decreased 23%; half-life: decreased 44%; Norethindrone: AUC decreased 18%; half-life: decreased 15%	Use alternative contraceptive method
Nevirapine Ethinyl estradiol / Norethindrone acetate 615	Red: Avoid combination	Do not coadminister: Reduced levels of ethinyl estradiol and progesterone	Possible contraceptive failure		Ethinyl estradiol 0.035 mg / Norethindrone 1 mg x 1 dose	Ethinyl estradiol AUC decreased 19%; Cmax no significant change. Norethindrone AUC decreased 18%	Use alternative contraceptive method
Nevirapine ATV 614	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Decreased atazanavir effects	Not studied	400 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 19%; Cmax no significant change; Cmin decreased 59%	Use alternative agents
Nevirapine ATV 613	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Decreased atazanavir effects	No significant change	300 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 42%; Cmax decreased 28%; Cmin decreased 72%	Use alternative agents
Nevirapine Artemether / Lumefantrine 612	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine			artemether / lumefantrine 80 mg / 480 mg x 6 doses	Lumefantrine AUC increased 56%; Cmax increased 24%; half-life: no significant change; clearance: decreased 36%	Use alternative agents
Nevirapine Artemether / Lumefantrine 611	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine	Potentially increased treatment failure		artemether / lumefantrine 80 / 480 mg	Lumefantrine AUC decreased 21%; Cmax decreased 30%	Use alternative agents
Nevirapine Artemether / Lumefantrine 610	Red: Avoid combination	Do not coadminister: Reduced levels of arthemether / lumifantrine	Potentially increased treatment failure		artemether / lumefantrine 80 / 480 mg	Artemether AUC decreased 72%; Cmax decreased 61%; Lumefantrine AUC decreased 21%; Cmax decreased 30%	Use alternative agents
Nevirapine SOF/VEL 609	Red: Avoid combination	Do not coadminister: Potential for reduced levels of sofosbuvir	Potential loss of anti-HCV efficacy	Nevirapine AUC decreased 79%; Cmax decreased 20%; Cmin decreased 60%; half-life: decreased 66%		Potential decrease in sofosbuvir and velpatasvir levels).	Use alternative agents
Nevirapine St. John's Wort (Hypericum perforatum) 608	Red: Avoid combination	Do not coadminister: Potential for reduced levels of NVP	loss of virologic response			Not studied	Contraindicated. Use alternative agents
Nevirapine Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide 607	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Potentially decreased or increased elvitegravir, cobicistat and / or nevirapine effects	Not studied		Not studied	Use alternative agents
Nevirapine EBR/GZR 606	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Decreased elbasvir, grazoprevir levels expected	Nevirapine AUC decreased 31%; Cmax decreased 36%; Cmin decreased 21%		Not studied (may decrease grazprevir levels)	Contraindicated. Use alternative agents.
Nevirapine EBR/GZR 605	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Potentially decreased elbasvir, grazoprevir levels expected			Not studied (may decrease grazprevir levels)	Avoid combination. Use alternative agents
Nevirapine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 604	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dasabuvir, ombitasvir, and paritaprevir	Potential decrease in HCV agent efficacy	Nevirapine AUC decreased 27% (at week 4); Nevirapine AUC no significant change (at week 10)Nevirapine AUC with rifampicin approximates nevirapine baseline without rifampicin at week 10.		Not studied (may decrease paritaprevir levels)	Use alternative agents
Nevirapine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 603	Red: Avoid combination	Do not coadminister: Potential for reduced levels of anti-HCV agents	Potential decrease in anti-HCV efficacy			Not studied (may decrease paritaprevir levels)	Use alternative agents
Etravirine Phenytoin 556	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and phenytoin	Potential decreased etravirine effects; potential decreased anticonvulsants effects
Etravirine CBZ 555	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and carbamazepine	Potential decreased etravirine effects; potential decreased anticonvulsants effects
Etravirine Phenobarbital 554	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine and phenobarbital	Potential decreased etravirine effects; potential decreased anticonvulsants effects				Avoid combination and use alternative agents
Etravirine NVP 553	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine					Avoid combination: :combining two NNRTIs has not been shown beneficial use alternate agents
Etravirine EFV 552	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine					Avoid combination: combining two NNRTIs has not been shown beneficial; use alternate agents
Etravirine SOF/VEL 551	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir and voxilaprevir	Potential loss of anti-HCV efficacy	Not studied		Not studied (may decrease velpatasvir and voxilaprevirlevels)	Contraindicated. Use alternative agents.
Etravirine SOF/VEL 550	Red: Avoid combination	Do not coadminister: potientially reduced levels of velpatasvir	Potential loss of anti-HCV efficacy	Not studied		Not studied (may decrease velpatasvir and sofosbuvir levels)	Contraindicated. Use alternative agents.
Etravirine Pimavanserin 549	Red: Avoid combination	Do not coadminister: potientially reduced levels of pimavanserin	Potential decreased pimavanserin effects				Contraindicated. Use alternative agents.
Etravirine Cariprazine 548	Red: Avoid combination	Do not coadminister: potientially reduced levels of cariprazine	Potential decreased cariprazine effects				Contraindicated. Use alternative agents.
Etravirine Lumateperone 547	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Decreased Lumateperon levels				Avoid combination and use alternative agents
Etravirine G/P 546	Red: Avoid combination	Do not coadminister: Potential for reduced levels of glecaprevir / Pibrentasvir	Potentially decreased glecaprevir / pibrentasvir levels expected			Not studied (may decrease grazprevir levels)	Avoid combination. Use alternative agents
Etravirine RIF 545	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etravirine	Significant decrease in etravirine efficacy
Etravirine RPT 544	Red: Avoid combination	Do not coadminister: Potential for reduced levels of etraviorine	Potential decreased etravirine effects
Etravirine St. John's Wort (Hypericum perforatum) 543	Red: Avoid combination	Do not coadminister: Potential for reduced levels of ETR	loss of virologic response	Not studied		Not studied	Contraindicated. Use alternative agents.
Etravirine EBR/GZR 542	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elbasvir / grazoprevir	Potentially decreased elbasvir, grazoprevir levels expected	Not studied		Not studied (may decrease grazprevir levels)	Avoid combination. Use alternative agents
Etravirine DTG 541	Red: Avoid combination	Do not coadminister: Potential for reduced levels of dolutegravir	Potentially reduced dolutegravir effectiveness		50 mg daily	Dolutegravir AUC decreased 71%; Cmin decreased 88%	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. If one of these boosted PIs is present and known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
Etravirine Bedaquiline 540	Red: Avoid combination	Do not coadminister: Potential for reduced levels of bedaquiline	potentially reduced levels of bedaquiline
Etravirine ATV/c 539	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy	Not studied		Not studied; Potential decreased atazanavir and cobicistat levels)	Use alternative agents
Etravirine Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 538	Red: Avoid combination	Do not coadminister: Potential for reduced levels of anti-HCV agents	Potential decrease in anti-HCV efficacy	Not studied		Not studied (may decrease paritaprevir levels)	Use alternative agents
Etravirine DTG 537	Red: Avoid combination	Administer standard doses			50 mg daily	Dolutegravir AUC increased 11%; Cmin increased 28%	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. When using this combo and there is known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
Etravirine DTG 536	Red: Avoid combination	Administer standard doses	Potentially reduced dolutegravir effectiveness		50 mg daily	Dolutegravir AUC decreased 25%; Cmin decreased 37%	Do not coadminister etravirine with dolutegravir unless atazanavir / ritonavir, darunavir / ritonavir, or lopinavir / ritonavir are also part of the regimen. When using this combo and there is known or clinically suspected INSTI resistance, increase dolutegravir dosage to 50 mg BID.
Efavirenz Saquinavir 469	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Potential loss of antiviral efficacy		1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Use alternative agents
Efavirenz Saquinavir 468	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Potential loss of antiviral efficacy		1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Use alternative agents
Efavirenz SOF/VEL 467	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir and voxilaprevir			Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 466	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir and voxilaprevir			Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 465	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir and voxilaprevir			Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 464	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir		400 / 100 mg daily x 14 days	Velpatasvir AUC decreased 53%, Cmin 57%, Cmax decreased 47%. Sofobuvir Cmax increased 38%.	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 463	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir		400 / 100 mg daily x 14 days	Velpatasvir AUC decreased 53%, Cmin 57%, Cmax decreased 47%. Sofobuvir Cmax increased 38%.	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 462	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir		Efavirenz Cmin decreased 19%; AUC decreased 15%; Cmax deceased 10%	400 mg / 100 mg for 14 days	Sofosbuvir Cmax increased 38%. Velpatasvir Cmax decreased 47%; AUC decreased 53%; Cmin decreased 57%	Contraindicated. Use alternative agents.
Efavirenz Ethinyl estradiol / Norethindrone acetate 461	Red: Avoid combination	Do not coadminister: Reduced levels of progestin		No significant change	Ethinyl estradiol 50 mcg x 1 dose	No significant change	Use alternative contraceptive method
Efavirenz Etonogestrel 460	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of etonogestrel				Use alternative contraceptive method
Efavirenz Etonogestrel 459	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of etonogestrel			Etonogestrel decreased 61%	Use alternative contraceptive method
Efavirenz Etonogestrel 458	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of etonogestrel			Etonogestrel decreased 61%	Use alternative contraceptive method

Subscribe to Red: Avoid combination